Industry Symposium Supported by GSK

Chair(s)

• 

  Joseph Mikhael, MD

  Professor in Clinical Genomics and Therapeutics
  Translational Genomics Research Institute (TGen), City of Hope Cancer Center
  Scottsdale, Arizona

Presentations:

• 08:00 - 08:10 East Coast USA Time

  What more can we do: The first relapse treatment landscape
  

  Speaker: Paul G. Richardson, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
• 08:10 - 08:25 East Coast USA Time

  The road ahead: Driving outcomes in RRMM
  

  Speaker: Peter M. Voorhees, MD – Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
• 08:25 - 08:35 East Coast USA Time

  Leaving no patient behind: Patient preferences at relapse
  

  Speaker: Lisa B. Leypoldt, MD (she/her/hers) – University Medical Center Hamburg-Eppendorf, Germany

  Speaker: Martine Elias, M.Sc. (she/her/hers) – Myeloma Canada
• 08:35 - 08:45 East Coast USA Time

  Optimizing patient outcomes: Balancing efficacy and safety
  

  Speaker: Joseph Mikhael, MD – Translational Genomics Research Institute (TGen), City of Hope Cancer Center